Corporate & Investor Presentation

Capital allocation $ in millions 3Q22 Higher priority . Reinvest in product development for Cash and cash equivalents $202 Reinvest for growth high-return organic growth 7-8% of revenue invested in R&D Debt $681 Net debt $479 Pursue M&A Free cash flow $69 Actively evaluate potential acquisitions Pursue targets aligned with long-term strategic goals and financial objectives Unused borrowing capacity $1,570 NOTE: Values may not calculate due to rounding Support dividends Regular return of cash to shareholders through dividend at a level that is meaningful and sustained During 3Q22 $67M invested in R&D (8% of revenue) Paid $61M in dividends to shareholders Lower priority 29 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 Opportunistically • repurchase shares Current program suspended following Opportunistic repurchase of shares acquisitions of MatrixCare and Propeller ResMed

View entire presentation